Old malaria and HIV drugs repurposed to fight ovarian cancer

NCT ID NCT06971744

Recruiting now Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether combining two drugs that affect cell cleanup (hydroxychloroquine and nelfinavir) with standard maintenance therapy (bevacizumab) can help keep ovarian cancer from growing back. About 38 women with recurrent high-grade serous ovarian cancer will take these pills plus an IV infusion every three weeks. The study will check safety and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hydroxychloroquine, nelfinavir, and bevacizumab
What this could lead to: If it works, this could offer a new maintenance option to delay cancer progression in patients with recurrent ovarian cancer.
What could go wrong: This is a small, early-phase trial (38 participants) with no control group, so results may not be conclusive. The drugs can cause side effects like nausea or vision changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Medical University of South Carolina
RECRUITING

Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.